Maxygen Inc. (MAXY) filed Amended Quarterly Report for the period ended 2008-06-30.
Maxygen Inc. is a leader in the emerging field of directed molecular evolution the process by which genes are modified for specificcommercial uses. The proprietary technologies known as MolecularBreedingmimic the natural process of evolution and bring together advances in molecular biology and classical breeding while capitalizing on the large amount of genetic information generated by government academic and commercial laboratories. Maxygen Inc. has a market cap of $340.06 million; its shares were traded at around $8.83 with a P/E ratio of 8.7 and P/S ratio of 14.68. Maxygen Inc. had an annual average earning growth of 4.9% over the past 5 years.
Highlight of Business Operations:
More on MAXY: